13F Pro13F Pro

DAFNA Capital Management LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1389933
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare91.8%$481.3M
  • Other8.2%$43.1M

AUM History

13fpro.ai/research/fund/dafna-capital-management-llc-1389933

Conviction and streaks

Concentrating · top 10 = 56.2%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

RVMD$RVMDConviction hold20.1% weight · held 10 quarters$Conviction hold5.9% weight · held 10 quartersCMPS$CMPSConviction hold5.4% weight · held 10 quartersSTXS$STXSConviction hold4.5% weight · held 10 quartersNKTR$NKTRConviction hold4.2% weight · held 5 quartersNKTR$NKTRAccumulating+3084% shares · 4 quarters runningPODD$PODDAccumulating+801% shares · 2 quarters runningHELP$HELPAccumulating+13% shares · 2 quarters runningNGNE$NGNEAccumulating+218% shares · 2 quarters runningRVMD$RVMDTrimming-17% shares · 4 quarters running$Trimming-53% shares · 4 quarters runningCYTK$CYTKTrimming-57% shares · 4 quarters runningAXGN$AXGNTrimming-72% shares · 3 quarters running$Trimming-58% shares · 3 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/dafna-capital-management-llc-1389933

DAFNA Capital Management LLC 13F holdings — Q2 2026

$524.4M portfolio (+19.3% QoQ) · 88 holdings · Q2 2026 13F · top 10 are 56% of the stock portfolio

All holdings — DAFNA Capital Management LLC (Q2 2026)

88 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
RCUS$RCUSArcus Biosciences, Inc.$13.6M-0.5%
ASND$ASNDAscendis Pharma A/S$12.9M-99%
NBIX$NBIXNEUROCRINE BIOSCIENCES INC$9.7M-18%
AXGN$AXGNAxogen, Inc.$9.7M-16%
PODD$PODDINSULET CORP$9.4M+469%
EWTX$EWTXEdgewise Therapeutics, Inc.$9.2M+102%
BCAX$BCAXBicara Therapeutics Inc.$8.5M-32%
— ISHARES NASDAQ BIOTECH INDX - ETFetf/fund$8.1M-31%
SNDX$SNDXSyndax Pharmaceuticals Inc$7.3M+54%
MPLT$MPLTMapLight Therapeutics, Inc.$6.1M—
LRMR$LRMRLarimar Therapeutics, Inc.$6.1M-1%
IPSC$IPSCCentury Therapeutics, Inc.$5.9M-1%
DXCM$DXCMDEXCOM INC$5.8M—
IMVT$IMVTImmunovant, Inc.$5.8M-0.7%
INGN$INGNInogen Inc$5.5M—

What changed in Q2 2026

Against the previous quarter's 13F: 14 new, 17 added to, 29 trimmed, 8 sold out. Share-count changes; largest moves by dollar size first.

New positions (14)

  • KYMR$KYMRKymera Therapeutics, Inc.$3.1M

    first bought this quarter

  • ANL$ANLAdlai Nortye Group Ltd.$2.8M

    first bought this quarter

  • NGEN$NGENNERVGEN PHARMA CORP.$2.2M

    first bought this quarter

  • RNA.R1599901$RNA.R1599901Avidity Biosciences, Inc.$1.7M

    first bought this quarter

  • EPRX$EPRXEUPRAXIA PHARMACEUTICALS INC.$1.5M

    first bought this quarter

  • DSGN$DSGNDesign Therapeutics, Inc.$1.5M

    first bought this quarter

+8 more in the Excel export

Added to (17)

  • DNLI$DNLIDenali Therapeutics Inc.+132%

    now $19.0M · held 6 qtrs

  • NKTR$NKTRNEKTAR THERAPEUTICS+93%

    now $22.2M · held 5 qtrs, 5 adds in a row

  • PODD$PODDINSULET CORP+469%

    now $9.4M · held 10+ qtrs, 2 adds in a row

  • EWTX$EWTXEdgewise Therapeutics, Inc.+102%

    now $9.2M · held 10+ qtrs

  • SNDX$SNDXSyndax Pharmaceuticals Inc+54%

    now $7.3M · held 10+ qtrs

  • KIDS$KIDSORTHOPEDIATRICS CORP+98%

    now $3.6M · held 2 qtrs, 2 adds in a row

+11 more in the Excel export

Trimmed (29)

  • ASND$ASNDAscendis Pharma A/S-99%

    now $12.9M · held 10+ qtrs

  • SPDR S&P BIOTECH ETF - ETF-38%

    now $31.1M

  • BHVN$BHVNBiohaven Ltd.-84%

    now $2.0M · held 10+ qtrs, 2 trims in a row

  • MBX$MBXMBX Biosciences, Inc.-93%

    now $652K · held 4 qtrs

  • CMPS$CMPSCOMPASS Pathways plc-17%

    now $28.5M · held 10+ qtrs

  • BCAX$BCAXBicara Therapeutics Inc.-32%

    now $8.5M · held 7 qtrs

+23 more in the Excel export

Sold out (8)

  • DAWN$DAWNDay One Biopharmaceuticals, Inc.was $21.0M

    held 9+ qtrs

  • KALV$KALVKalVista Pharmaceuticals, Inc.was $5.4M

    held 9+ qtrs

  • FULC$FULCFulcrum Therapeutics, Inc.was $1.6M

    held 1 qtr

  • ORIC$ORICOric Pharmaceuticals, Inc.was $945K
  • ZBIO$ZBIOZenas BioPharma, Inc.was $831K
  • NAMS$NAMSNewAmsterdam Pharma Co N.V.was $640K

+2 more in the Excel export

Firm AUM (Form ADV): $645.2M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F DAFNA Capital Management LLC has filed, 41 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow DAFNA Capital Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of DAFNA Capital Management's top 20 holdings: 36/100 (our AI quality score, weighted by position size; 13 of the 20 are scored)

Top 10 since filing

-17.0%

Value-weighted move of the 10 largest stock positions

Turnover

13%

Last quarter; 38% over the last 4

Top 10 weight

56%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

91%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

DAFNA Capital Management LLC disclosed 88 positions worth $524.4M in its Form 13F-HR for Q2 2026, led by $RVMD (Revolution Medicines, Inc.) at 20.1% of the equity portfolio. During the quarter the fund opened 14 new positions and exited 8 — including a new stake in $KYMR and a full exit from $DAWN. The portfolio is most concentrated in Healthcare (91.8% of disclosed assets). All figures are sourced directly from DAFNA Capital Management LLC’s Form 13F-HR filing with the SEC under CIK 1389933.

Funds like this

managers whose biggest positions overlap DAFNA Capital Management's
Paradigm Biocapital Advisors LP$5.34B 13F book · 3 shared top holdingsRVMDEWTXMPLTCasdin Capital, LLC$2.00B 13F book · 6 shared top holdingsRVMDDNLINGNEANLBAKER BROS. ADVISORS LP$19.96B 13F book · 11 shared top holdingsRVMDALKSIMVTIDYABVF INC/IL$3.91B 13F book · 6 shared top holdingsRVMDNKTRALKSSTOKDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 8 shared top holdingsRVMDLRMRIDYAXENEIntegral Health Asset Management, LLC$2.53B 13F book · 4 shared top holdingsRVMDCYTKEWTXNBIX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: DAFNA Capital Management LLC

13F Pro is an AI hedge fund tracker and stock research platform. For DAFNA Capital Management LLC (SEC CIK: 1389933), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in DAFNA Capital Management LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.